Seres Therapeutics Inc. (MCRB) has disclosed a new risk, in the Supply Chain category.
Seres Therapeutics Inc. is confronted with the business risk that its reliance on Nestlé for accurate and comprehensive commercialization data of VOWST could lead to significant repercussions if such data are flawed. Since Nestlé’s reporting on VOWST net sales informs Seres Therapeutics’ financial statements and strategic decisions, any inaccuracies or omissions could detrimentally impact Seres’ operations and stock price. Furthermore, this dependency heightens the risk of misinforming investors, as the company’s projections and reported results hinge on the integrity of the data provided by Nestlé. Consequently, the success of VOWST and the company’s financial health remain vulnerable to the accuracy of Nestlé’s reporting.
The average MCRB stock price target is $5.05, implying 376.42% upside potential.
To learn more about Seres Therapeutics Inc.’s risk factors, click here.
